After some nonprofit organizations made noise about the U.S. Army’s plans to license a Zika vaccine to Sanofi, several lawmakers say it’s a bad idea.

On Wednesday, Gilead CEO John Milligan shared some clues into what might be next for the ailing drugmaker.

Remember when Valeant was counting on a sales force beef-up to revive its struggling GI franchise? It may have just run into a big problem in that department.…

​​​​​​​Big Pharma might not like billionaire John Arnold’s latest move any more than they did his first. After helping cost-effectiveness watchdog ICER get…

Allergan CEO Brent Saunders has said it before, and he’ll say it again: He’s not interested in buying Valeant.

Biosimilar competition for Amgen’s blockbuster rheumatoid arthritis drug Enbrel is lurking in the background, but the biotech may have found a way to help…

Pharma’s top U.S. execs haven’t been shy about expressing their desire for tax reform—and now, they’re taking those wishes directly to Congress.

Pharma execs and boards essentially pressed pause on dealmaking as 2016 came to a close, with uncertainties about the U.S. presidential election—and a Donald…

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…